コレステロール吸収を調節するアルブミンナノキャリアを用いたアボカドの皮抽出物の口服投与
Laura M Teixeira1,2,3, Ana S Viana1,2, Catarina P Reis3,4
1Centro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.
Pharmaceutics
|August 28, 2025
まとめ
牛の血清アルブミンナノ粒子にアボカドの皮の抽出物をナノカプセル化することで,その安定性と生物利用性が向上します. この新しい投与システムは,コレステロールの吸収を減らすことで高コレステロール血症の管理の可能性を示しています.
科学分野:
- バイオテクノロジー
- ナノ医療
- 栄養薬
背景:
- 高コレステロール血症は心臓血管疾患の主な危険因子であり,現在の薬は有害な影響を及ぼします.
- 自然製品には代替品がありますが 生物学的利用可能性が低いため 先進的な配送システムが必要になります
- アボカド (Persea americana) の皮のエキスは,コレステロールを下げる可能性を示しています.
研究 の 目的:
- 牛の血清アルブミンのナノ粒子を開発し特徴づけ,ペルシア・アメリカナの皮のエキスを封じ込める.
- ナノ製剤の安定性,安全性,生物利用性を評価する.
- コレステロールの吸収を減らすためのナノ製剤の有効性を評価する.
主な方法:
- アボカドの皮の抽出物は,牛の血清アルブミンナノ粒子にカプセル化されました.
- ナノ製剤の物理化学的特性,安定性,および細胞毒性を評価した.
- 生物利用性とコレステロール吸収はCaco-2細胞モデルを用いて評価された.
主要な成果:
- ナノカプセル化により,抽出物の安定性と生物利用性が改善され,シミュレートされた消化過程で保護されました.
- ナノ粒子は好ましい物理化学的性質を示し,安全性と生物相容性を実証した.
- ナノ製剤は,自由抽出物と比較して,Caco-2細胞におけるコレステロールの浸透を著しく減少させた.
結論:
- アボカドの皮のエキスのナノ製剤は,安定した,生物利用可能な経口投与システムを提供します.
- このナノ製剤は高コレステロール血症の治療に 有望で安全な戦略です
- 代謝障害の管理におけるさらなる応用が提案されています.
関連する概念動画
Lipid Absorption
708
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
708
Lipid Digestion
93.8K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
93.8K
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
4.4K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
4.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Drug Delivery: Enteral Route
709
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
709
Non-Oral Extravascular Drug Absorption Routes
294
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
294


